Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RestorAATion-2 (WVE-006) in Pi*ZZ Alpha-1 Antitrypsin Deficiency
2024-511981-36-00Phase 2Authorised
- Sponsor
- Wave Life Sciences
- Start
- Dec 2024
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 6
01
Overview
Phase 2, open-label trial of WVE-006 in alpha-1 antitrypsin deficiency (AATD) (2 arms), sponsored by Wave Life Sciences. Primary endpoint: Safety (Adverse Events). Planned start Dec 2024; status: authorised.
02
Drugs
WVE-006
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on 2024-511981-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511981-36-00.